Psma-targeted activated myeloid cells as a novel prostate cancer immunotherapy
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110671
- Recipient
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $1,228,125
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Baltimore, MD 21218, USA
Award details come from USAspending.gov.
About this award
The Johns Hopkins University was awarded a $1,228,125 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research titled "PSMA-TARGETED ACTIVATED MYELOID CELLS AS A NOVEL PROSTATE CANCER IMMUNOTHERAPY" from September 2021 through September 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research, including investigating medical solutions for battlefield care. This award will allow Johns Hopkins researchers to develop an immunotherapy for prostate cancer using myeloid cells targeted to the prostate-specific membrane antigen.
Quick answers
Who received award W81XWH2110671?
W81XWH2110671 was awarded to The Johns Hopkins University by Medical Command (Department of the Army) on September 1, 2021.
How much is award W81XWH2110671 worth?
$1,228,125 has been obligated on W81XWH2110671.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award